Ignore the noise in GLP-1 stocks. Find the best value instead.

Let's start with the background. Currently there are four branded and patent-protected GLP-1 weight-loss drugs on the market. Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE ...

Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... who has a strong educational background in mathematics and computer sciences. His father, Henry B.R. Brown invented ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...

“My background in biochemistry ... Working alongside a specialist diabetes dietitian at Novo Nordisk, he developed recipes that ticked every box: nutritious, affordable and, most importantly, ...

Against that background, Lilly is launching 7.5-milligram ... before increasing the dosage to 5 milligrams. While Lilly and Novo Nordisk (NVO) (DK:NOVO.B) are leaders in the field for now, many ...